Buprenorphine-naloxone (Suboxone) to treat opioid use disorder

In this podcast, Dr. Tina Hu and Dr. Adam Pyle describe in detail how to treat opioid use disorder with buprenorphine-naloxone (Suboxone). They cover which patients are good candidates, how it compares to methadone, how it should be administered, what needs to happen in terms of follow-up. They discuss all of this in the context of the latest evidence.Dr. Tina Hu is a family medicine resident physician at St. Michael's Hospital in Toronto. Dr. Adam Pyle is a staff family physician at St. Michael's Hospital and also practises emergency medicine at Lakeridge Health Oshawa, in Oshawa, Ontario.They co-authored a peer-reviewed practice article published in the Canadian Medical Association Journal. It is titled "Five things to know about...Buprenorphine-naloxone."Full practice article (subscription required): www.cmaj.ca/lookup/doi/10.1503/cmaj.180776-----------------------------------This podcast episode is brought to you by Audi Canada.The Canadian Medical Association has partnered with Audi Canada to offer CMA members a preferred incentive on select vehicle models. Purchase any new qualifying Audi model and receive an additional cash incentive based on the purchase type. Details of the incentive program can be found at www.audiprofessional.ca.-----------------------------------Subscribe to CMAJ Podcasts on Apple Podcasts, iTunes, Google Play, Stitcher, Overcast, Instacast, or your favourite aggregator. You can also follow us directly on our SoundCloud page or you can visit www.cmaj.ca/page/multimedia/podcasts.Comments or questions? Text us.Join us as we explore medical solutions that address the urgent need to change healthcare. Reach out to us about this or any episode you hear. Or tell us about something you'd like to hear on the leading Canadian medical podcast.You can find Blair and Mojola on X @BlairBigham and @DrmojolaomoleX (in English): @CMAJ X (en français): @JAMC FacebookInstagram: @CMAJ.ca The CMAJ Podcast is produced by PodCraft Productions

There are no comments yet.

Please log in to write the first comment.